Best Practices and Research Advances in Thoracic Oncology: A Regional Series SE Asia Course 1: Liquid Biopsy in Lung Cancer-Liquid Biopsy in Advance Disease

Video Transcription

Video Summary

Dr. Charu Agarwal, a professor at the University of Pennsylvania, discusses the significance of liquid biopsy in advanced non-small cell lung cancer. She highlights how targeted therapy has improved patient survival rates substantially over the past two decades. The emphasis is on precise and personalized therapy through molecular testing such as Next-Generation Sequencing (NGS). Dr. Agarwal explains the importance of biomarker testing in treatment decisions and the role of liquid biopsy alongside tissue biopsy for identifying actionable alterations. Barriers to testing, including patient anxiety and tissue availability, are acknowledged. Ensuring timely and comprehensive molecular profiling enhances outcomes and lowers toxicity.

Asset Subtitle

Charu Aggarwal, MD, MPH

Keywords

liquid biopsy

non-small cell lung cancer

targeted therapy

Next-Generation Sequencing

biomarker testing